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In this issue ofNeuron, Maruyama et al. (2013) demonstrate the binding of a new class of selective tau ligands,
termed PBBs, to tau deposits in transgenic mice and in human subjects with normal cognition, Alzheimer’s
disease, or a corticobasal syndrome.Alzheimer’s disease (AD) is characterized
postmortem by the frequent co-occur-
rence of deposits of two different amyloid
proteins, amyloid-beta (Ab) plaques and
neurofibrillary tangles (NFTs), consisting
of hyperphosphorylated tau (Hyman
et al., 2012). Each type of deposit has
its own distinct regional pattern of distri-
bution (Braak and Braak, 1997). Over the
past ten years, much progress has been
realized in developing and applying posi-
tron emission tomography (PET) imaging
radiopharmaceuticals to assess Ab
plaque load in vivo in human subjects.
This was accomplished initially with the
Ab-selective PET radioligand [11C]PiB
(Klunk et al., 2004) and more recently
with four different 18F-labeled Ab-selec-
tive radioligands (Rowe and Villemagne,
2013), resulting in the approval of one of
these 18F-labeled agents (Amyvid) by the
U.S. Food and Drug Administration for
clinical use as an Ab plaque imaging
agent. What has been missing from the
research scene, until very recently, is the
availability of a tau-selective PET radioli-
gand to track tau deposits in AD and other
clinical syndromes neuropathologically
classified as tauopathies (Spillantini and
Goedert, 2013). Because the occurrence
of Ab plaques and NFTs overlap in many
brain regions in AD, PET radioligands
with good selectivity for Ab or tau are
necessary to accurately assess the
relative concentration of each protein.
Nonselective PET radioligands, such as
[18F]FDDNP (Shin et al., 2011), bind to
both Ab plaques and NFTs, and accurate
quantitation of the amount of each protein
present in many brain regions is not
achievable. Hence, the field has soughtto develop tau-selective PET radioligands
that would complement existing Ab-se-
lective PET radioligands to image AD,
as well as presymptomatic AD subjects
(Morris et al., 2010; Sperling et al., 2011).
Such an agent would likely prove useful
in following the clinical progression of
AD, because NFT concentrations appear
to reflect severity of clinical symptoms
(Nagy et al., 1995), while Ab plaques
appear at an early (presymptomatic)
stage and level off relatively early in the
disease process (Hyman et al., 1993). An
important use of tau-selective PET radio-
pharmaceuticals will be to assess tau
load (or the loss or absence of tau load)
in anti-tau or anti-Ab therapeutic clinical
trials. Several clinical trials are under
way to test the Ab-cascade hypothesis
in Ab-positive cognitively normal sub-
jects, and the addition of a tau-selective
PET radioligand to Ab-selective radioli-
gands in these trials would provide
additional important insights into the
pathophysiology of AD.
A tau-selective PET radioligand could
potentially prove extremely useful in
non-AD tauopathies as well. These
include neurodegenerative diseases
such as frontal temporal lobar degenera-
tion (FTLD), Pick’s disease, corticobasal
degeneration (CBD), and progressive
supranuclear palsy (PSP). In their pure
form, these dementias are characterized
by tau deposits without the co-occur-
rence of Ab plaques. It is important to
note that tau deposits are of variable
composition across these diseases. In
AD, there are six different isoforms of
hyperphosphorylated tau (varying in size
from 352 to 441 amino acids). Three ofNeuron 79, Septhe tau isoforms possess a three-repeat
region, while three isoforms possess a
four-repeat region. These repeat regions
are believed to be responsible for the
extended b-pleated sheet (amyloid)
nature of these tau deposits. The various
non-AD tauopathies contain differing
combinations of these isoforms. If a tau-
selective PET radioligand bound to all
types of tau deposits, regardless of the
combination of isoforms, it would find
additional important uses in imaging the
non-AD tauopathies. However, it is
possible that a radioligand might bind
well only to three-repeat tau isoforms
and not be effective in imaging other
tauopathies comprised mainly of four-
repeat isoforms. For this reason, it is
critical to assess the binding properties
of the tau-selective radioligand to a
variety of tau isoforms.
Previous progress in the development
of tau-selective PET radioligands has
been reported recently by two different
groups: the Tohoku University/Austin
Hospital Melbourne group have reported
a series of 18F-labeled THK compounds
(Harada et al., 2013; Okamura et al.,
2013) and the Siemens/Lilly group have
reported the 18F-labeled T807 and T808
compounds (Chien et al., 2013a, 2013b).
Both groups have focused initially upon
the binding of their tau-selective radioli-
gands in AD brain, and little information
regarding binding properties of these
radioligands to the non-AD tauopathies
has been reported to date. In this issue
of Neuron, Maruyama et al. (2013)
describe the in vitro and in vivo properties
of a new class of selective tau-binding
ligands they term PBBs. Some of thetember 18, 2013 ª2013 Elsevier Inc. 1035
Figure 1. Chemical Structures of the Ab-Selective
Ligand, PiB, and Two New Tau Ligands, PBB3 and
PBB1
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used in in vitro assays and in vivo op-
tical imaging studies in a transgenic
tauopathy mouse model, while the
most promising PBB ligand (termed
PBB3) was radiolabeled with 11C
and used in PET imaging studies in
the tauopathy mouse model and in
elderly cognitively normal, AD, and
CBD subjects (a four-repeat pre-
dominant tauopathy).
There are advantages and disad-
vantages with the choice of 11C
versus 18F radiolabels. The longer
half-life of 18F (109.8 min) permits
the regional distribution of the
radiopharmaceutical from a cen-
tral nuclear pharmacy production
center and provides generally more
convenient PET imaging logistics
relative to the shorter half-life 11C
(20.4 min) radionuclide. However
for research imaging purposes, the
11C radiolabel permits two or more serial
PET studies to be conducted in the
same subject with different radiopharma-
ceuticals on the same day several hours
apart.
Maruyama et al. (2013) screened a
number of fluorescent compounds for
selective binding of the ligands to tau
deposits (from both AD and non-AD
tauopathies) over Ab plaques. They found
that compounds with extended con-
jugated backbones with a core length of
15–18 A˚ bound most favorably to tau.
The conjugated butadiene linkage be-
tween the two aromatic ring systems of
PBBs apparently provides the basis for
their high tau binding affinities. It is inter-
esting to note the structural similarities
between PiB and PBB3 (Figure 1), yet
their binding affinities to aggregated Ab
and tau are very different. Just as surpris-
ing is the difference in selectivity between
PBB1 (which also binds Ab plaques) and
PBB3 (Figure 1) on tissue sections—
although large differences in lipophilicity
may account for this.
In vitro and ex vivo fluorescence imag-
ing of tau inclusions with PBBs utilized
PS19 transgenic mice expressing a
FTDP-17 four-repeat tau isoform with
the P301S mutation, and tau deposits
were apparent in the brain stem and
spinal cord of these mice. Other fluo-
rescence imaging experiments were
conducted in a second mouse model of1036 Neuron 79, September 18, 2013 ª2013tauopathy (rTg4510 mice expressing the
FTDP-17 four-repeat P301L mutation),
and these mice demonstrated specific
binding of PBBs to neuronal tau inclu-
sions in the neocortex and hippocampus.
In addition, several PPBs were radiola-
beled with 11C and examined in these
mice after intravenous injection using
ex vivo autoradiographic analysis and
microPET imaging. [11C]PBB3 performed
well in these experiments and demon-
strated low nonspecific binding, high
specific binding to tau deposits, and
saturable specific binding.
The binding of [11C]PBB3 was com-
pared to that of [11C]PiB using in vitro
autoradiography of hippocampal sections
of AD and control brains, and clear bind-
ing differences were observed. This is
consistent with specific binding of [11C]
PBB3 to tau deposits in NFTs and neuro-
pil threads and the absence of specific
[11C]PiB binding to these structures. PET
imaging studies with [11C]PBB3 were
conducted in subjects with normal cogni-
tion, probable AD, or probable CBD and
compared with [11C]PiB scans. [11C]
PBB3 showed lower nonspecific white-
matter binding than [11C]PiB in all sub-
jects, but probable AD subjects showed
elevated retention of with [11C]PBB3 in
medial temporal regions relative to [11C]
PiB as well as high levels of [11C]PBB3
retention in lateral temporal and frontal
cortical areas relative to the control sub-Elsevier Inc.jects. One unexplained anomaly of
[11C]PBB3 binding was retention in
the dural venous sinuses in all sub-
jects. In general, the in vivo behavior
of [11C]PBB3 in the brains of prob-
able AD and control subjects was
consistent with that of a tau-selec-
tive radiopharmaceutical and was
distinctly different from the binding
pattern of the Ab-selective imaging
agent [11C]PiB.
PET scans using [11C]PiB and
[11C]PBB3 in the single CBD sub-
ject resulted in low levels of [11C]
PiB retention throughout the brain
but significant retention of [11C]
PBB3 in neocortical and subcor-
tical regions. This is the first re-
ported apparently successful PET
imaging study of tau deposits in a
non-AD four-repeat predominant
tauopathy using a tau-selective
radiopharmaceutical.Overall, the PBB3 tau imaging results
presented by Maruyama et al. (2013) are
highly encouraging and provide strong
support for the tau-selective binding of
the ligand to tau deposits in two FTDP-
17 transgenic mouse models and in vivo
in AD and CBD subjects. The pharmaco-
kinetic properties of the radioligand are
generally favorable, with rapid brain
uptake, relatively fast clearance of tracer
from brain regions containing low tau
loads, reversible specific binding of the
tracer in tau-containing brain regions,
and the absence of lipophilic radiolabeled
metabolites in the blood. However,
several issues remain to be explored and
further evaluated in future imaging studies
using this tracer, including (1) the basis of
the relatively high retention of the tracer
in the dural venous sinuses of human
subjects; (2) binding and imaging data in
three-repeat predominant tau isoform
cases such as Pick’s disease; (3) the
practical impact of the relatively low
specific signal of [11C]PBB3 in brain re-
gions of high tau load (only 1.5 SUVR
units) with respect to detection sensitivity
limits in a variety of subjects; (4) thorough
pharmacokinetic analyses of the radio-
ligand in control, probable AD, and three-
and four-repeat non-AD tauopathies; (5)
critical comparison of the properties of
[11C]PBB3 relative to those of other puta-
tive tau-selective PET imaging agents
such as the 18F-labeled THK compounds
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Previewsand T807 and T808; and ultimately (6)
validation of tau quantification in corre-
lative imaging-postmortem studies as
have been done for several Ab-imaging
tracers. While much work remains to be
accomplished in future investigations,
the initial in vivo tau imaging studies with
[11C]PBB3 presented by Maruyama et al.
(2013) are promising in many respects.
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The subventricular zone (SVZ) continuously supplies new interneurons that incorporate into pre-existing
olfactory bulb circuitry. Khodosevich et al. (2013) show that connective tissue growth factor (CTGF) regulates
a multicellular signaling cascade determining the number of postnatally born inhibitory interneurons in odor-
activated glomeruli.Robust neurogenesis takes place in the
subventricular zone (SVZ) of the adult
mouse brain (Luskin, 1993). The neuro-
blasts, generated in the SVZ, travel along
the rostral migratory stream, arrive at the
core of the olfactory bulb (OB), and
migrate radially until their appearance in
either the granule cell layer or the glomer-
ular layer (Lois and Alvarez-Buylla, 1994;
Luskin, 1993). Subsequently, the neuro-
blasts differentiate in their respectivelayers into the two major interneurons:
granule cells and periglomerular cells.
Each day, thousands of neuroblasts
migrate to the OB and integrate into pre-
existing circuits after differentiating.
The majority end up in the granule layer,
while the rest end their journey in
the glomerular layer based on their
fate that was established in the SVZ
(Luskin, 1993; Merkle et al., 2007). This
continual flux of cells provides the sub-strate to selectively incorporate new
cells and remodel the olfactory circuitry
that processes sensory input. In this
issue of Neuron, Khodosevich et al.
(2013) show that odorant-activated
expression of the previously character-
ized connective tissue growth factor,
CTGF, controls the survival of periglomer-
ular cells by potentiating TGFb2 activity
and activating an apoptotic pathway in
periglomerular cells in selective glomeruli.tember 18, 2013 ª2013 Elsevier Inc. 1037
